Background: Lung cancer has been the most common diagnosed cancer and the leading cause of cancer-related death. Growing evidence has demonstrated that circular RNAs (circRNAs) are closely associated with the occurrence and progression of tumors. Ferroptosis is an iron-dependent form of cell death triggered by the accumulation of lipid peroxides, and it has been considered as a potential target for cancer therapy. However, the specific mechanism by which circRNAs modulate ferroptosis in lung cancer remains largely unknown. Methods: Through retrieval from The Cancer Genome Atlas (TCGA) database, the differential expression of AFF4 mRNA in lung cancer was identified. Further screening and validation revealed that circAFF4, a circular RNA derived from AFF4 host gene, also exhibited a similar trend in lung cancer. Subsequently, quantitative reverse transcription-PCR (qRT-PCR) and fluorescent in situ hybridization (FISH) were used to detect its expression pattern and distribution. Functional studies were conducted both in vitro and in vivo to determine the biological functions of circAFF4. Furthermore, the interaction between circAFF4 and ubiquitin-specific peptidase 10 (USP10) as well as the relationship between USP10 and Glutathione peroxidase 4 (GPX4), were investigated by biotin-labeled RNA pull-down, mass spectrometry, RNA immunoprecipitation (RIP), FISH and co-immunoprecipitation (Co-IP) assays. Results: Here we demonstrated that circAFF4 was significantly downregulated in lung cancer tissues and lung cancer cells. In vitro and in vivo experiments suggested that circAFF4 inhibited the proliferation of lung cancer cells and promoted ferroptosis. Mechanistically, circAFF4 bound to the deubiquitinating enzyme USP10, which in turn suppressed USP10-mediated deubiquitination of GPX4, and enhanced the ubiquitin-dependent proteasome degradation of GPX4, thereby facilitating ferroptosis in lung cancer cells. Conclusions: Our findings reveal a novel mechanism by which circAFF4 interacts with USP10, impairing USP10-mediated stabilization of GPX4, promoting ferroptosis in lung cancer cells, and ultimately suppressing lung cancer progression. The circAFF4/USP10/GPX4 axis provides a new direction and may be a potential target for lung cancer treatment.
Introduction: Colorectal cancer (CRC) remains one of the most lethal malignancies globally. Chemoresistance or reduced chemosensitivity is a key factor contributing to treatment failure in CRC, particularly in patients with advanced-stage disease. Iroquois homeobox protein 4 (IRX4), a transcription factor expressed in multiple tissues, has been demonstrated to be implicated in the progression of many cancers. Based on this background, IRX4 identified through Illumina Infinium 935K methylation chip analysis was chosen to explore its potential role in CRC. Methods: Following initial screening via the Illumina Infinium 935K methylation chip, we further confirmed the hypermethylation of IRX4 in CRC tissues using pyrosequencing technology. The expression levels of IRX4 were determined by immunofluorescence (IF) staining, reverse transcription-quantitative polymerase chain reaction (RT-qPCR), and western blot (WB) assays. In vitro cell experiments evaluated the effects of IRX4 overexpression on the proliferation, invasion, migration, and apoptosis of CRC cells, as well as its impact on the chemosensitivity to oxaliplatin (OXA). Mechanistically, after IRX4 overexpression, the phosphorylation level of epidermal growth factor receptor (EGFR) in CRC cells was detected. Luciferase reporter gene assays and immunofluorescence staining were used to investigate the effects of IRX4 overexpression on the activation of the nuclear factor-κB (NF-κB) pathway and the nuclear translocation of the p65 subunit. Results: IRX4 was downregulated in CRC tissues and cell lines, and its expression was negatively correlated with tumor invasion depth and poor prognosis. In vitro experiments demonstrated that the overexpression of IRX4 inhibited CRC cell proliferation, migration, and invasion and promoted apoptosis. Moreover, IRX4 overexpression enhanced the chemosensitivity of CRC cells to OXA. Mechanistically, IRX4 overexpression significantly inhibited the TNF-α-induced NF-κB transcriptional activity and suppressed the nuclear translocation of NF-κB p65 in CRC cells. Furthermore, combined treatment with OXA and IRX4 overexpression significantly reduced the levels of EGFR and the phosphorylationlevels of EGFR downstream signaling molecules. Conclusion: These findings suggest that IRX4 may be a prognostic biomarker and therapeutic target in CRC. Moreover, IRX4 might regulate CRC progression and chemosensitivity by inhibiting the NF-κB /EGFR pathway, suggesting its potential as a therapeutic target to improve chemotherapeutic efficacy in CRC.
Hexokinase 2 (HK2), a key enzyme in the Warburg effect, is associated with poor prognosis in colorectal cancer (CRC). HK2 is known to exert glycolysis-inde